Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | Flavodoxin/Radical SAM superfamily/Wyosine base formation, putative | 0.0238 | 0.3504 | 0.3033 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0238 | 0.3504 | 0.5 |
Brugia malayi | diaphorase | 0.0071 | 0.0676 | 0.0676 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0622 | 1 | 1 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0313 | 0.478 | 0.478 |
Echinococcus granulosus | methionine synthase reductase | 0.0384 | 0.5976 | 0.5976 |
Trypanosoma brucei | S-adenosyl-L-methionine-dependent tRNA 4-demethylwyosine synthase, putative | 0.0238 | 0.3504 | 0.3033 |
Plasmodium vivax | flavodoxin domain containing protein | 0.0551 | 0.8804 | 0.8717 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0308 | 0.47 | 1 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0622 | 1 | 1 |
Brugia malayi | Partitioning defective-6 homolog alpha | 0.0038 | 0.0124 | 0.0124 |
Loa Loa (eye worm) | AGC/PKC/IOTA protein kinase | 0.0114 | 0.1416 | 0.1416 |
Leishmania major | hypothetical protein, conserved | 0.0238 | 0.3504 | 0.3033 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0384 | 0.5976 | 0.5976 |
Brugia malayi | protein kinase C3,putative | 0.0107 | 0.1292 | 0.1292 |
Echinococcus granulosus | cytochrome b5 reductase 4 | 0.0071 | 0.0676 | 0.0676 |
Giardia lamblia | Hypothetical protein | 0.0551 | 0.8804 | 1 |
Echinococcus granulosus | peripheral plasma membrane protein CASK | 0.0031 | 0.0004 | 0.0004 |
Brugia malayi | flavodoxin family protein | 0.0238 | 0.3504 | 0.3504 |
Echinococcus granulosus | NADH cytochrome b5 reductase 3 | 0.0071 | 0.0676 | 0.0676 |
Loa Loa (eye worm) | hypothetical protein | 0.0622 | 1 | 1 |
Mycobacterium tuberculosis | Possible electron transfer protein FdxB | 0.0071 | 0.0676 | 0.5 |
Mycobacterium tuberculosis | Probable monooxygenase | 0.0071 | 0.0676 | 0.5 |
Trichomonas vaginalis | NADPH fad oxidoreductase, putative | 0.0551 | 0.8804 | 0.8159 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0238 | 0.3504 | 0.5 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0622 | 1 | 1 |
Echinococcus multilocularis | cytochrome b5 reductase 4 | 0.0071 | 0.0676 | 0.0676 |
Schistosoma mansoni | cell polarity protein | 0.0038 | 0.0124 | 0.0124 |
Chlamydia trachomatis | Na(+)-translocating NADH-quinone reductase subunit F | 0.0071 | 0.0676 | 0.1131 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0551 | 0.8804 | 1 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0622 | 1 | 1 |
Leishmania major | p450 reductase, putative | 0.0622 | 1 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.0384 | 0.5976 | 0.5976 |
Echinococcus multilocularis | peripheral plasma membrane protein CASK | 0.0031 | 0.0004 | 0.0004 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0622 | 1 | 1 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0622 | 1 | 1 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.0071 | 0.0676 | 0.5 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0238 | 0.3504 | 0.5 |
Echinococcus multilocularis | methionine synthase reductase | 0.0384 | 0.5976 | 0.5976 |
Schistosoma mansoni | MAGUK homolog | 0.0031 | 0.0004 | 0.0004 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0238 | 0.3504 | 0.5 |
Onchocerca volvulus | 0.0071 | 0.0676 | 1 | |
Echinococcus granulosus | Microtubule-associated serine/threonine-protein kinase | 0.0031 | 0.0004 | 0.0004 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0622 | 1 | 1 |
Loa Loa (eye worm) | flavodoxin family protein | 0.0238 | 0.3504 | 0.3504 |
Trypanosoma cruzi | Flavodoxin/Radical SAM superfamily/Wyosine base formation, putative | 0.0238 | 0.3504 | 0.3033 |
Echinococcus multilocularis | protein kinase c iota type | 0.0117 | 0.1463 | 0.1463 |
Treponema pallidum | flavodoxin | 0.0238 | 0.3504 | 1 |
Plasmodium vivax | hypothetical protein, conserved | 0.0238 | 0.3504 | 0.3033 |
Trypanosoma cruzi | NADPH--cytochrome P450 reductase, putative | 0.0238 | 0.3504 | 0.3033 |
Loa Loa (eye worm) | cytochrome b5 reductase 4 | 0.0071 | 0.0676 | 0.0676 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0622 | 1 | 1 |
Mycobacterium tuberculosis | Possible oxygenase | 0.0071 | 0.0676 | 0.5 |
Leishmania major | cytochrome P450 reductase, putative | 0.0551 | 0.8804 | 0.8717 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0384 | 0.5976 | 0.5976 |
Onchocerca volvulus | 0.0031 | 0.0004 | 0.0056 | |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0622 | 1 | 1 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0622 | 1 | 1 |
Mycobacterium tuberculosis | Hypothetical oxidoreductase | 0.0071 | 0.0676 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0622 | 1 | 1 |
Echinococcus multilocularis | NADH cytochrome b5 reductase 3 | 0.0071 | 0.0676 | 0.0676 |
Loa Loa (eye worm) | diaphorase | 0.0071 | 0.0676 | 0.0676 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0622 | 1 | 1 |
Schistosoma mansoni | cytochrome B5 | 0.0071 | 0.0676 | 0.0676 |
Loa Loa (eye worm) | AGC/MAST/MAST protein kinase | 0.0031 | 0.0004 | 0.0004 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0308 | 0.47 | 1 |
Plasmodium falciparum | S-adenosyl-L-methionine-dependent tRNA 4-demethylwyosine synthase, putative | 0.0238 | 0.3504 | 0.3033 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0622 | 1 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0238 | 0.3504 | 0.5 |
Chlamydia trachomatis | sulfite reductase | 0.0384 | 0.5976 | 1 |
Loa Loa (eye worm) | PAR-6 protein | 0.0038 | 0.0124 | 0.0124 |
Echinococcus granulosus | cytochrome b5 reductase 4 | 0.0071 | 0.0676 | 0.0676 |
Echinococcus multilocularis | partitioning defective protein 6 | 0.0038 | 0.0124 | 0.0124 |
Echinococcus multilocularis | microtubule associated serine:threonine protein | 0.0031 | 0.0004 | 0.0004 |
Schistosoma mansoni | atypical protein kinase C | 0.0124 | 0.1587 | 0.1587 |
Brugia malayi | Cytochrome b5-like Heme/Steroid binding domain containing protein | 0.0071 | 0.0676 | 0.0676 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0622 | 1 | 1 |
Plasmodium falciparum | NADPH--cytochrome P450 reductase, putative | 0.0238 | 0.3504 | 0.3033 |
Schistosoma mansoni | NADH-cytochrome B5 reductase | 0.0071 | 0.0676 | 0.0676 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0622 | 1 | 1 |
Schistosoma mansoni | diflavin oxidoreductase | 0.0308 | 0.47 | 0.47 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0622 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0622 | 1 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.0622 | 1 | 1 |
Trypanosoma cruzi | p450 reductase, putative | 0.0622 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0622 | 1 | 1 |
Echinococcus granulosus | protein kinase c iota type | 0.0117 | 0.1463 | 0.1463 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
F (ADMET) | = 5 % | Evaluated for the time by which 50% of total naproxen is formed in 80% human serum at a pH of 7.4 | ChEMBL. | 10780905 |
Jss (ADMET) | = 0.6 nM hr-1 cm**-2 | Evaluated for the Steady-state fluxes (Jss) for delivery of total Naproxen species through excised human skin in vitro in isotonic phosphate buffer (0.05 M) at pH 5.0 | ChEMBL. | 10780905 |
Jss (ADMET) | = 0.6 nM hr-1 cm**-2 | Evaluated for the Steady-state fluxes (Jss) for delivery of total Naproxen species through excised human skin in vitro in isotonic phosphate buffer (0.05 M) at pH 5.0 | ChEMBL. | 10780905 |
Jss (ADMET) | = 7.7 nM hr-1 cm**-2 | Evaluated for the Steady-state fluxes (Jss) for delivery of total Naproxen species through excised human skin in vitro in isotonic phosphate buffer (0.05 M) at pH 7.4 | ChEMBL. | 10780905 |
Jss (ADMET) | = 7.7 nM hr-1 cm**-2 | Evaluated for the Steady-state fluxes (Jss) for delivery of total Naproxen species through excised human skin in vitro in isotonic phosphate buffer (0.05 M) at pH 7.4 | ChEMBL. | 10780905 |
Kp (ADMET) | = 4000 cm hr-1 | Evaluated for the permeability coefficients for delivery of total Naproxen species through excised human skin in vitro in isotonic phosphate buffer (0.05 M) at pH 5.0 | ChEMBL. | 10780905 |
Kp (ADMET) | = 4000 cm hr-1 | Evaluated for the permeability coefficients for delivery of total Naproxen species through excised human skin in vitro in isotonic phosphate buffer (0.05 M) at pH 5.0 | ChEMBL. | 10780905 |
Kp (ADMET) | = 20000 cm hr-1 | Evaluated for the permeability coefficients for delivery of total Naproxen species through excised human skin in vitro in isotonic phosphate buffer (0.05 M) at pH 7.4 | ChEMBL. | 10780905 |
Kp (ADMET) | = 20000 cm hr-1 | Evaluated for the permeability coefficients for delivery of total Naproxen species through excised human skin in vitro in isotonic phosphate buffer (0.05 M) at pH 7.4 | ChEMBL. | 10780905 |
logD | = 1.02 | Evaluated for the apparent partition coefficient between 1-octanol and phosphate buffer at pH 5.0. | ChEMBL. | 10780905 |
logD | = 3.04 | Evaluated for the apparent partition coefficient between 1-octanol and phosphate buffer at pH 7.4 | ChEMBL. | 10780905 |
Solubility (ADMET) | = 141.6 mM | Evaluated for the solubility in aqueous solution at pH 5.0 | ChEMBL. | 10780905 |
Solubility (ADMET) | = 432 mM | Evaluated for the solubility in aqueous solution at pH 7.4 | ChEMBL. | 10780905 |
T1/2 (ADMET) | = 0.7 day | Evaluated for the hydrolysis rate in phosphate buffer at pH 7.4 at 37 degrees centigrade | ChEMBL. | 10780905 |
T1/2 (ADMET) | = 18 day | Evaluated for the hydrolysis rate in phosphate buffer at 5.0 at 37 degrees centigrade. | ChEMBL. | 10780905 |
T1/2 (ADMET) | = 4 min | Evaluated for the hydrolysis rate in 80% human serum (mean; n=2) at a pH of 7.4 | ChEMBL. | 10780905 |
T1/2 (ADMET) | = 4 min | Evaluated for the hydrolysis rate in 80% human serum (mean; n=2) at a pH of 7.4 | ChEMBL. | 10780905 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.